Multigene predictors in early-stage breast cancer: Moving in or moving out?

Expert Review of Molecular Diagnostics

Volumn 8, Issue 2, 2008, Pages 129-135

  Ross, Jeffrey S ^a  

^a ALBANY MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BREAST CANCER; CANCER DIAGNOSIS; CANCER GRADING; CANCER STAGING; COMPARATIVE STUDY; EDITORIAL; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENOMICS; IMMUNOHISTOCHEMISTRY; MARKET; MICROARRAY ANALYSIS; PREDICTION; PREDICTOR VARIABLE; PROGNOSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BREAST NEOPLASMS; FEMALE; GENE EXPRESSION PROFILING; GENOME, HUMAN; HUMANS; PREDICTIVE VALUE OF TESTS; PROGNOSIS;

EID: 41549100210     PISSN: 14737159     EISSN: 17448352     Source Type: Journal    
DOI: 10.1586/14737159.8.2.129     Document Type: Editorial

References (44)

1. Perou CM, Sorlie T, Eisen MB et al. Molecular portraits of human breast tumours. Nature 406, 747-752 (2000).
2. Ross JS, Linette GP, Stec J et al. Breast cancer biomarkers and molecular medicine. Expert Rev. Mol. Diagn. 3(5), 573-585 (2003).
3. Sotiriou C, Wirapati P, Loi S et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl Cancer Inst. 98, 262-272 (2006).
4. Pusztai L, Cristofanilli M, Paik S. New generation of molecular prognostic and predictive tests for breast cancer. Semin. Oncol. 34, S10-S16 (2007).
5. Stec J, Wang J, Coombes K et al. Comparison of the predictive accuracy of DNA array-based multigene classifiers across cDNA arrays and Affymetrix GeneChips. J. Mol. Diagn. 7, 357-367 (2005).
6. Gruvberger-Saal SK, Cunliffe HE, Carr KM, Hedenfalk IA. Microarrays in breast cancer research and clinical practice - the future lies ahead. Endocr. Relat. Cancer 13, 1017-1031 (2006).
7. Ross JS, Symmans WF, Pusztai L, Hortobagyi GN. Standardizing slide-based assays in breast cancer: hormone receptors, HER2, and sentinel lymph nodes. Clin. Cancer Res. 13, 2831-2835 (2007).
8. Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin. Cancer Res. 11, 5678-5685 (2005).
9. Liedtke C, Mazouni C, Hess KR et al. Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J. Clin. Oncol. (2008) (Epub ahead of print).
10. Whitehead CM, Nelson R, Hudson P et al. Selection and optimization of a panel of early stage breast cancer prognostic molecular markers. Modern Pathol. 18, 55A (2006).
11. Ring BZ, Seitz RS, Beck R et al. Novel prognostic immunohistochemical biomarker panel for estrogen receptor-positive breast cancer. J. Clin. Oncol. 24, 3039-3047 (2006).
12. Davis LM, Harris C, Tang L et al. Amplification patterns of three genomic regions predict distant recurrence in breast carcinoma. J. Mol. Diagn. 9, 327-336 (2007).
13. Paik S, Shak S, Tang G et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 351, 2817-2826 (2004).
14. Cobleigh MA, Tabesh B, Bitterman P et al. Tumor gene expression and prognosis in breast cancer patients with 10 or more positive lymph nodes. Clin. Cancer Res. 11(24 Pt 1), 8623-8631 (2005).
15. Harris L, Fritsche H, Mennel R et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J. Clin. Oncol. 25, 5287-5312 (2007).
16. Lo SS, Norton J, Mumby PB et al. Prospective multicenter study of the impact of the 21-gene recurrence score (RS) assay on medical oncologist (MO) and patient (pt) adjuvant breast cancer (BC) treatment selection. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25(18S), 577 (2007).
17. Sparano JA. TAILORx: Trial Assigning Individualized Options for Treatment (Rx). Clin. Breast Cancer 7, 347-350 (2006).
18. Goetz MP, Suman VJ, Ingle JN et al. A two-gene expression ratio of homeobox 13 and interleukin-17B receptor for prediction of recurrence and survival in women receiving adjuvant tamoxifen. Clin. Cancer Res. 12, 2080-2087 (2006).
19. Garber K. Gene expression tests foretell breast cancer's future. Science 303, 1754-1755 (2007).
20. Perreard L, Fan C, Quackenbush JF et al. Classification and risk stratification of invasive breast carcinomas using a real-time quantitative RT-PCR assay. Breast Cancer Res. 8, R23 (2006).
21. Bogaerts J, Cardoso F, Buyse M et al. Gene signature evaluation as a prognostic tool: challenges in the design of the MINDACT trial. Nat. Clin. Pract. Oncol. 3, 540-551 (2006).
22. Wang Y, Klijn JG, Zhang Y et al. Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679 (2005).
23. Foekens JA, Atkins D, Zhang Y et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 24, 1665-1671 (2006).
24. Liu R, Wang X, Chen GY et al. The prognostic role of a gene signature from tumorigenic breast-cancer cells. N. Engl. J. Med. 356, 217-226 (2007).
25. Ayers M, Symmans WF, Stec J et al. Gene expression profiles predict complete pathologic response to neoadjuvant paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide chemotherapy in breast cancer. J. Clin. Oncol. 22, 2284-2293 (2004).
26. Rouzier R, Pusztai L, Delaloge S et al. Nomograms to predict pathologic complete response and metastasis-free survival after preoperative chemotherapy for breast cancer. J. Clin. Oncol. 23, 8331-8339 (2005).
27. Wagner P, Wang B, Clark E, Lee H, Rouzier R, Pusztai L. Microtubule associated protein (MAP)-tau: a novel mediator of paclitaxel sensitivity in vitro and in vivo. Cell Cycle 4, 1149-1152 (2005).
28. Goetz MP, Rae JM, Suman VJ et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J. Clin. Oncol. 23, 9312-9318 (2005).
29. Jin Y, Desta Z, Stearns V et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J. Natl Cancer Inst. 97, 30-39 (2005).
30. Goetz MP, Knox SK, Suman VJ et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res. Treat. 101, 113-121 (2007).
31. Ioannidis JP. Is molecular profiling ready for use in clinical decision making? Oncologist 12, 301-311 (2007).
32. Arup www.arup.com
33. Ipsogen Cancer Profiler www.ipsogen.com
34. BD Diagnostics www.bd.com/tripath/labs/mo_oncology.asp
35. Applied Genomics, Inc. www.applied-genomics.com
36. eXagen DIAGNOSTICS, Inc.™ www.exagen.com
37. Agendia™ www.agendia.com
38. OncoMed Pharmaceuticals www.oncomed.com
39. Genomic Health Oncotype DX® www.genomichealth.com/oncotype/default. aspx
40. AviaraDx www.aviaradx.com
41. Celera www.celera.com
42. Veridex, LLC www.veridex.com
43. Nuvera Biosciences www.nuverabio.com
44. Roche AmpliChip CYP450 www.roche.com/med_backgr-ampli.htm